Cargando…

Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents

BACKGROUND: A patient reported outcome (PRO) instrument with evidence of validity and reliability for assessing symptoms of eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) is needed to measure treatment benefit in clinical trials. The aim of this research is to develop an EG/EGE s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Calvin N., O’Quinn, Sean, Bailey, Julie, Meyers, Oren, Slagle, Ashley F., Dellon, Evan S., Datto, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611867/
https://www.ncbi.nlm.nih.gov/pubmed/34819137
http://dx.doi.org/10.1186/s13023-021-02107-6
_version_ 1784603374452211712
author Ho, Calvin N.
O’Quinn, Sean
Bailey, Julie
Meyers, Oren
Slagle, Ashley F.
Dellon, Evan S.
Datto, Catherine
author_facet Ho, Calvin N.
O’Quinn, Sean
Bailey, Julie
Meyers, Oren
Slagle, Ashley F.
Dellon, Evan S.
Datto, Catherine
author_sort Ho, Calvin N.
collection PubMed
description BACKGROUND: A patient reported outcome (PRO) instrument with evidence of validity and reliability for assessing symptoms of eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) is needed to measure treatment benefit in clinical trials. The aim of this research is to develop an EG/EGE symptom PRO instrument for patients aged 12 and above. METHODS: The Symptom Assessment for Gastrointestinal Eosinophilic Diseases (SAGED) was developed through a literature review, discussions with expert clinicians, and concept elicitation and cognitive debriefing interviews with patients. Patients (n = 28) were recruited based on confirmed diagnosis and self-reported symptoms. The final instrument was translated and linguistically validated with additional cognitive debriefing interviews (n = 105). RESULTS: SAGED is a 24-h recall questionnaire consisting of eight items evaluating the core symptoms of EG and EGE (abdominal pain, nausea, bloating, early satiety, loss of appetite, vomiting, and diarrhea). Seven of the eight items are evaluated on an 11-point numerical rating scale ranging from ‘none’ to ‘worst imaginable’. Cognitive debriefing interviews showed that adults and adolescents understand the content and are able to select a response that reflects their experience. The linguistic validation process produced 21 translations that are understandable to patients and conceptually equivalent to the source version. CONCLUSIONS: SAGED is suitable for measuring symptom improvement in adult and adolescent patients with EG and/or EGE. The content validity of SAGED has been established through best practices in qualitative research for PRO instrument development. The psychometric properties of SAGED will be evaluated in a future study.
format Online
Article
Text
id pubmed-8611867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86118672021-11-29 Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents Ho, Calvin N. O’Quinn, Sean Bailey, Julie Meyers, Oren Slagle, Ashley F. Dellon, Evan S. Datto, Catherine Orphanet J Rare Dis Research BACKGROUND: A patient reported outcome (PRO) instrument with evidence of validity and reliability for assessing symptoms of eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) is needed to measure treatment benefit in clinical trials. The aim of this research is to develop an EG/EGE symptom PRO instrument for patients aged 12 and above. METHODS: The Symptom Assessment for Gastrointestinal Eosinophilic Diseases (SAGED) was developed through a literature review, discussions with expert clinicians, and concept elicitation and cognitive debriefing interviews with patients. Patients (n = 28) were recruited based on confirmed diagnosis and self-reported symptoms. The final instrument was translated and linguistically validated with additional cognitive debriefing interviews (n = 105). RESULTS: SAGED is a 24-h recall questionnaire consisting of eight items evaluating the core symptoms of EG and EGE (abdominal pain, nausea, bloating, early satiety, loss of appetite, vomiting, and diarrhea). Seven of the eight items are evaluated on an 11-point numerical rating scale ranging from ‘none’ to ‘worst imaginable’. Cognitive debriefing interviews showed that adults and adolescents understand the content and are able to select a response that reflects their experience. The linguistic validation process produced 21 translations that are understandable to patients and conceptually equivalent to the source version. CONCLUSIONS: SAGED is suitable for measuring symptom improvement in adult and adolescent patients with EG and/or EGE. The content validity of SAGED has been established through best practices in qualitative research for PRO instrument development. The psychometric properties of SAGED will be evaluated in a future study. BioMed Central 2021-11-24 /pmc/articles/PMC8611867/ /pubmed/34819137 http://dx.doi.org/10.1186/s13023-021-02107-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ho, Calvin N.
O’Quinn, Sean
Bailey, Julie
Meyers, Oren
Slagle, Ashley F.
Dellon, Evan S.
Datto, Catherine
Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title_full Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title_fullStr Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title_full_unstemmed Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title_short Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
title_sort development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611867/
https://www.ncbi.nlm.nih.gov/pubmed/34819137
http://dx.doi.org/10.1186/s13023-021-02107-6
work_keys_str_mv AT hocalvinn developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT oquinnsean developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT baileyjulie developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT meyersoren developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT slagleashleyf developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT dellonevans developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents
AT dattocatherine developmentandcontentvalidationofasymptomassessmentforeosinophilicgastritisandeosinophilicgastroenteritisinadultsandadolescents